A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis - Trial NCT06260267
Access comprehensive clinical trial information for NCT06260267 through Pure Global AI's free database. This Phase 1 trial is sponsored by Ferring Pharmaceuticals and is currently Not yet recruiting. The study focuses on Ulcerative Colitis. Target enrollment is 90 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Ferring Pharmaceuticals
Timeline & Enrollment
Phase 1
Mar 20, 2024
Sep 15, 2025
Primary Outcome
Treatment-emergent adverse events from baseline to week 52
Summary
To explore the safety of FE 999322 (microbiota suspension) and FE 999324 (microbiota capsule)
 versus placebo in subjects with active mild to moderate ulcerative colitis (UC).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06260267
Non-Device Trial